Search This Blog

Monday, November 11, 2024

'We're going to have to fix this ourselves': 4 CFOs on navigating Medicare Advantage

 Medicare Advantage now provides health coverage to around 55% of the nation’s seniors, but some hospitals and health systems are choosing to end contracts with some MA plans due to administrative hurdles. The most frequently cited challenges include high prior authorization denial rates and delayed payments from insurers.

Becker's connected with four health system CFOs at our 12th Annual CEO-CFO Roundtable on Nov. 11 to understand how hospital finance leaders are navigating Medicare Advantage today.

Question: Medicare Advantage plans are growing in popularity, but health systems often cite challenges stemming from prior authorizations and reimbursement rates. How are you navigating these challenges to ensure your organization can still provide high-quality care to seniors while managing financial pressures?

Jim Molloy, Executive Vice President, CFO, Treasurer, Ochsner Health
We're going to have to fix this ourselves. The Medicare Advantage segment of the population is growing, and it’s going to become a larger and larger part of the system. We will eventually need to figure something out, but it won’t be easy.

The reality is, no one really makes money off Medicare, and that’s something we have to address. I've been hearing about this issue for over 30 years. Back then, the goal was to make it work, but the difference now is that the math has changed. We no longer have a growing commercial population to offset the losses. The fastest-growing segment of our population is Medicare-eligible, and more people are moving into MA.

While I do think we need to push back on the insurers, I believe the more fundamental issue is that politicians aren’t addressing the core problem: the fact that Medicare isn’t profitable, and it covers a huge portion of the population. No one is tackling this problem head-on.

At my institution, we are already facing hundreds of millions of dollars in costs, whether from inefficiency or other factors. The inflation we will experience on the cost side is going to outpace whatever Medicare is going to pay, even if insurers cut another 10%. While we fight the insurers, as an industry, we need to figure out how we'll deal with the rest of the challenges Medicare presents.

Matthew Cox, CFO, Corewell Health
We operate a very large Medicare Advantage plan, and when managed well, it works effectively. One of our core values is collaboration, and that extends across the company. While working internally is easier than working externally, we apply similar tactics in both contexts. We prioritize sharing information openly. For instance, if we're having trouble getting claims paid or facing issues with certain edits, we address those challenges together to reduce unnecessary friction.

That said, sometimes friction is necessary. When I wear both a health plan hat and a hospital hat, I understand that some level of friction helps ensure we’re doing the right thing. It’s important to make sure that the proper processes are in place and that the right decisions are being made.

We also contract with Medicare Advantage plans from a variety of payers and use payer scorecards to track performance. When denial rates are high or there’s excessive administrative friction with no real value, we sit down with the insurers to discuss what needs to change. In my experience, as long as we are firm but collaborative in addressing issues, we've had success working with some of the largest insurance companies in the country.

Of course, our situation might be different from that of a single critical access hospital, given our prominence in Michigan. But the underlying principle is the same: if we’re overturning 98% of denials, every denial represents wasted administrative costs. To address that, we use payer scorecards to demonstrate the problem and communicate that if these inefficiencies continue, we’ll need to adjust reimbursement rates to cover the extra costs incurred. We make it clear that these unnecessary hurdles yield no value.

Overall, we believe Medicare Advantage is here to stay, but it must be properly managed. We can’t allow payers to take advantage of the system without accountability.

Stephen DelRossi, CFO, Interim CEO, Northern Inyo Healthcare District
One of our biggest strategies is refusing to sign contracts. I recently read a report showing that Medicare Advantage denials have increased substantially in recent years. This is completely unsustainable for a community where around 49% of patients rely on Medicare.

To address this, I’ve been going out into the community, especially this time of year, to speak with senior citizens about their Medicare options. We recently held a large meeting to help them navigate the confusion, particularly around COVID-related changes to Medicare. I was very clear with them: while they can choose Medicare Advantage, we do not accept it unless they’re in a specific group that we work with.

Many of them were surprised to learn this, and it helped them understand why we have to be selective about which plans we accept. At the end of the day, we are committed to providing the services the community needs, but we also have to be realistic about the financial impact. The current proposals from payers, which would result in significant financial losses, are simply not sustainable. We cannot continue to absorb these losses.

David Krajewski, Executive Vice President and CFO, LifeBridge Health
About two years ago, we acquired a local health plan. In Maryland, the penetration of Medicare Advantage is much lower than the national average, around 20% compared to the 50% range elsewhere. As the penetration increases, we plan to participate in that growth. A key factor in this will be getting clinicians involved. It's essential that they understand the pre-authorization process and what needs to be done to avoid denials. Engaging clinical leadership and ensuring they’re on board with the contracts is crucial to navigating these challenges effectively.

Another important aspect is self-reflection. Healthcare is simply too expensive. When you look at the broader cultural and societal impact, it’s clear that we need to find ways to make healthcare more affordable. To that end, we scorecard our Medicare and Medicare Advantage plans, and we won’t hesitate to cancel contracts with those exhibiting poor behavior.

But self-reflection also applies internally. We need to ensure we are providing services in a cost-effective manner. For example, if we're doing a total knee replacement across the entire episode of care, we need to assess whether we’re more expensive than other hospitals in the state. Having this kind of data gives us significant leverage in negotiations with payers. If we find that we're too expensive, we need to figure out why and address it. Ultimately, it’s about holding ourselves accountable and ensuring we are doing our part to keep costs down while maintaining quality care.

https://www.beckershospitalreview.com/finance/were-going-to-have-to-fix-this-ourselves-4-cfos-on-navigating-medicare-advantage.html

CHS' $1B divestiture plan — 7 hospital sales to know

 Franklin, Tenn.-based Community Health Systems has completed or lined up multiple hospital sales this year as part of its divestiture plan, which aims to take in about $1 billion this year after offloading hospitals across various markets. 

CHS has sold 29 hospitals since 2020, but its long-term debt still stands at about $11.5 billion, with its debt exposure driving its M&A strategy. Despite recent reductions, CHS still has one of the highest debts among health systems, and remains focused on deleveraging its balance sheet.

"We continue to make progress toward our $1 billion divestiture plan," CFO Kevin Hammons said during the company's third-quarter earnings call. "We anticipate the majority of the remaining transactions to complete this plan will likely be signed in the fourth quarter, with final closings carrying over into the first quarter of 2025."

Here are seven hospital sales CHS has either proposed or completed so far this year: 

1-2. On Oct. 1, CHS sold Davis Regional Psychiatric Hospital and Davis Regional Medical Center in Statesville, N.C., to Iredell Health System. Iredell aims to keep the 42-bed behavioral health facility open and expand services at the acute care hospital. Financial terms of the deal were not disclosed. 

3. CHS on Aug. 1 sold Tennova Healthcare-Cleveland (Tenn.) to Vitruvian Health in Dalton, Ga. Vitruvian, which rebranded from Hamilton Health Care System as part of its regional expansion plans, acquired the 351-bed for $160 million. CHS may receive an additional cash payment based on potential changes to certain supplemental reimbursement programs. 

4. CHS plans to sell Merit Health Biloxi (Miss.), a 153-bed acute care hospital, to Gulfport, Miss.-based Memorial Health System. Memorial Health is a two-hospital system that has collaborated with Merit Health Biloxi across various service lines. Financial terms of the deal — which is expected to close in the first quarter — have not been disclosed. 

5-7. CHS signed a definitive agreement in August to sell its three Pennsylvania hospitals to nonprofit WoodBridge Healthcare. The proposed $120 million deal — which would see CHS exit Pennsylvania — is set to close in the fourth quarter, pending regulatory approvals and closing conditions.

https://www.beckershospitalreview.com/hospital-transactions-and-valuation/chs-1b-divestiture-plan-7-hospital-sales-to-know.html

'Moderna: share price down, a broker's analysis'

 Moderna is down nearly 6% in London, after Oddo BHF reduced its price target from $96 to $86.



The broker reports that despite a qualitative Q3, the stock remained under pressure at the end of the week.

The analyst cites the slower-than-anticipated ramp-up of its RSV vaccine, the commercial launch of its COVID/seasonal influenza vaccine scheduled for the 2026 season and, of course, questions about the future US government's position on vaccination programs.

The 2024 guidance adjusted at its September CMD has now been confirmed. Management is guiding the market towards sales of between $3 and $3.5 billion for the year.

'We maintain our Outperform recommendation in view of the company's current valuation and market opportunities. The interim phase 3 results in CytoMegaloVirus at the end of this year could in particular boost the share price", concludes Oddo BHF.

'US crude exports to China rebound from four-year low but outlook glum, Kpler says'

 U.S. exports of crude oil to China, the world's top oil importer, have rebounded in October from their lowest levels since 2020 amid weak Chinese fuel demand and refinery profits, but the outlook for growth in exports is glum, according to ship tracking service Kpler on Monday.

China's monthly imports of crude from the world's top producer hit 24,000 barrels per day (bpd) in August, the lowest levels since February 2020 when COVID-19 slashed demand. They have rebounded to about 134,000 and 130,000 bpd in September and October, respectively, Kpler data showed.

That, however, is still about half the average of 259,000 bpd in 2023, and weak Chinese demand has helped to reduce U.S. exports to Asia to a three-year low in October of 955,000 bpd.

"The economic weakness that we're seeing in China is playing through to refinery run weakness and ultimately weak demand for refined products," Kpler analyst Matt Smith said.

China's overall crude oil imports fell 9% in October, data showed on Thursday, the sixth consecutive month of year-over-year declines as the closure of a state oil refinery added to weaker demand from independent refiners.

Total imports fell to about 10.53 million bpd, data from the General Administration of Customs showed, recovering a bit from the July's 9.97 million bpd, the lowest level in 22 months.

SANCTIONED COUNTRIES

China increasingly has purchased its crude from U.S.-sanctioned countries such as Russia, Iran and Venezuela for cut-rate prices. The three combined accounted for about 3 million bpd, or about 30% of total October imports, Smith estimated.

China was the main destination of Venezuela's oil exports in October with 385,300 bpd shipped directly and indirectly, according to shipping data and documents from state oil firm PDVSA.

The expansion of the Tran Mountain pipeline (TMX) in May to nearly triple the crude flow from landlocked Alberta to Canada's Pacific coast also has boosted the number of shipments of Canadian crude heading directly to China, slashing exports from U.S. ports.

Crude exports from Vancouver to China touched a record 217,000 bpd in October, Kpler data showed.

Re-exports of Canadian oil from U.S. ports accounted for between 25% and 35% of U.S. crude exports annually to China in the last five years, according to Kpler.

GLUM OUTLOOK

The weakness in U.S. exports to China will likely continue, analysts said, as Beijing's efforts to stimulate economic growth will take time to take root and boost fuel demand.

"We shouldn't expect to see 600,000 to 700,000 bpd of demand growth from China going forward here, as we saw last decade," said Kpler's Smith.

More than half of China's auto sales last month were electric and plug-in hybrids, and sales of liquefied natural gas-fueled heavy trucks are rising, reducing demand for gasoline and diesel in transportation.

Chinese refiners' preference for sanctioned oil and barrels from the east of the Suez Canal also will remain a key factor, said Rohit Rathod, an analyst with ship tracking firm Vortexa.

Offsetting the glum outlook is an increase in government-approved import quota. China's 2025 quota for non-state-owned firms is up 5.8%, to 257 million metric tons, or 5.14 million bpd, the commerce ministry said last month.

The increase reflects in part the September startup of one of two new 200,000 bpd units at China's newest refiner, Yulong Petrochemical, buoying hope for higher imports.

https://www.msn.com/en-us/money/markets/us-crude-exports-to-china-rebound-from-four-year-low-but-outlook-glum-kpler-says/ar-AA1tTqW3

Israel Says It Has Met Most U.S. Demands on Gaza Aid as Deadline Looms

 Israel said on Monday it had met most demands by the United States to improve humanitarian conditions in Gaza but was still discussing some items as a deadline looms to improve the situation or face potential restrictions on U.S. military aid.

There are a number of things that remain under discussion and they touch on safety issues, an Israeli official told reporters. He said most issues had been addressed.

Among the U.S. demands that Israel appears to have refused is allowing the entry of 50-100 commercial trucks a day.

The official said commercial activity had been halted because Hamas was controlling the merchants. Restrictions on the entry of closed containers would also not be lifted due to security risks, the official said.

Others, including the opening of a fifth crossing into Gaza, have been implemented.

The United States told its ally Israel in a letter on Oct. 13 that it must take steps to improve the aid situation within 30 days, with Tuesday as the final deadline.

Last week, the State Department said Israel had taken some measures to increase aid access to Gaza but had so far failed to significantly turn around the humanitarian situation.

Israeli Foreign Minister Gideon Saar said on Monday he had met the U.S. ambassador and was confident that "we can reach an understanding with our American friends and that the issue will be solved".

Last week, a committee of global food security experts warned of a strong likelihood that famine is imminent in certain areas of northern Gaza, a claim which Israel rejected outright.

The Israeli official said Israel had added entrances into Gaza, expanded the humanitarian zone, increased security for aid vehicles and managed joint task forces with the international community and many others as part of the process to improve the humanitarian situation.

Israel began a wide military offensive in northern Gaza early last month. Linda Thomas-Greenfield, the U.S. envoy to the U.N., said on Oct. 16 that Washington was watching to ensure Israel's actions on the ground show it does not have a "policy of starvation" in the north.

https://www.usnews.com/news/world/articles/2024-11-11/israel-says-it-has-met-most-u-s-demands-on-gaza-aid-as-deadline-looms

Ardelyx cut to Neutral from Buy by Wainwright

 Target to $5.50 from $11

https://finviz.com/quote.ashx?t=ARDX&p=d

Hims & Hers Jumps: Explosive Growth, Insider Confidence, Big Money Moves

 Last week, Hims & Hers Health (NYSE:HIMS) dropped another mic with its latest earnings, and the numbers are mind-blowing. Revenue? Up 77% year-over-year to $401.6 millionblowing past every forecast in sight. Subscribers? Over 2 million, up 44% in just a year. Adjusted EBITDA? A jaw-dropping $51.1 million, more than quadruple last year's. And if that wasn't enough to turn heads, the company bumped its full-year revenue outlook to $1.465 billion. This isn't just growthit's rocket fuel for a business that's redefining personalized healthcare.

    Wall Street's big players are paying attention. Today, Robeco Institutional Asset Management, Diversify Advisory Services, and other institutional investors have all boosted their stakes, with a hefty 63.52% of the stock now in institutional hands. Meanwhile, insider moves are making waves too. Over the past several months, CEO Andrew Dudum and CFO Oluyemi Okupe sold some shares but held onto significant positionsalways a confidence signal. Analysts are buzzing as well, with TD Cowen raising its price target to $28, citing HIMS' diverse revenue streams and minimal reliance on buzzy GLP-1 weight-loss drugs (which account for less than 10% of revenue).

    And that's the kicker: Hims & Hers isn't banking everything on trendy weight-loss solutions. The company's secret sauce is its compounding personalization strategy, offering tailored solutions for everything from mental health to skincare. With a forward P/E under 28 and a ridiculously low PEG ratio of 0.15, HIMS is a bargain for the growth it's delivering. Throw in next year's plans to launch generic GLP-1 options, and you've got a long-term winner. Sure, the stock might see some bumpsit's been volatilebut this is a rare, transformational player in the telehealth space that investors should keep front and center.


    https://finance.yahoo.com/news/hims-hers-shares-jump-17-151509310.html